

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
October 16, 2012**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Somaxon Pharmaceuticals, Inc.

File No. 0-51665 - CF#28621

Somaxon Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on July 19, 2012.

Based on representations by Somaxon Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through July 19, 2022
Exhibit 10.2	through July 17, 2022
Exhibit 10.3	through July 19, 2022
Exhibit 10.4	through July 19, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Mara L. Ransom
Assistant Director